INO vaccine delivery system is applicable just to their own vaccine which is an underdog in the vaccine competition - they're also having a dispute with their manufacturing partner in regard to potential mass production -
Analyst commentary this morning -
fly -
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
Roth Capital analyst Jonathan Aschoff downgraded Inovio Pharmaceuticals to Sell from Neutral with an unchanged price target of $11. The stock closed Tuesday down $4.74 to $26.95. The company yesterday released "very limited" preliminary Phase 1 results from its trial with SARS-CoV-2 vaccine INO-4800, Aschoff tells investors in a research note. The analyst is "not encouraged by the complete absence of immune response details" and notes the denial of Inovio's injunction to force suppliers to share needed production technology. Aschoff says that despite its inclusion in the White House's Operation Warp Speed, he's "unimpressed that further preclinical work is required, rather than proceeding straight to later stage trials."
Maxim analyst Jason McCarthy downgraded Inovio (INO) to Hold from Buy. The analyst notes that the data in the company's Phase 1 clinical study of a COVID-19 vaccine candidate may have been "positive", but the stock is already up over 700% year-to-date and the potential success of INO-4800 appears to be priced in to the shares. McCarthy adds that Vaxart (VXRT) has also been selected to participate in a non-human primate challenge study as part of the government's "Operation Warp Speed" pandemic response, though given the recent surge in cases, there is room for "multiple players".
AI
